NPORE: Development, characterisation and validation of nanoparticles for adsorption of hydrophobic uremic toxins in renal failure patients
- Universität Hyderabad, Hyderabad, India
- Charité Universitätsmedizin Berlin, Medizinische Klinik IV, AG experimentelle Nephrologie and Hypertensiologie
- Helmholtz Zentrum Geesthacht, Zentrum for Biomaterialforschung, Teltow, Germany
Description of the project:
Patients with chronic kidney disease (CKD) and also those on dialysis (CKD-5D) show an increased cardiovascular mortality and morbidity due to several risk factors including hyperphosphataemia, diabetes mellitus, hypertension, anaemia, dyslipidemia and uremic retention solutes toxicity. Protein-bound uremic toxins, such as phenylacetic acid, indoxyl sulfate and p-cresylsulfate contribute substantially to the progression of chronic kidney disease and cardiovascular disease (CVD). However, based on their protein-binding these hydrophobic toxins are poorly cleared during conventional hemodialysis or even hemodiafiltration and thus accumulate in CKD-5Dpatients. Therefore, this project aims at the development, characterisation and validation of adsorbant particles for the removal of uremic toxins from plasma of chronic renal failure patients.
The consortium is composed of four partners covering synthetic, analytical and bio-safety and compatability aspects. HZG will develop new adsorbant particles and will modify already available (patent-protected) materials for the adsorption of uremic toxins. CHA will characterise the particles regarding their chemical and biochemical properties. EXC will use its strong experience in testing of biomaterials for biocompatibility aspects. UNH will test side effects, if any, of the particles on cultured human- blood cells (monocytes) and vascular endothelial and smooth muscle cells.
To ensure that our tests meet the requirements of our customers, we have established a quality system that fulfils all the requirements of DIN EN ISO/IEC 17025:2018 and ensures the implementation of our quality policy. This makes us an accredited testing and research institute in the areas mentioned. Our accreditation is valid in around 46 countries worldwide (including the EU, the USA and Japan), as a mutual recognition agreement, known as the ILAC Arrangement, applies between the laboratory accreditation bodies of these countries.